Hepatitis B vaccine

Abstract

A novel vaccine formulation is provided, comprising a hepatitis B component, particularly hepatitis B surface antigen, in combination with aluminum phosphate and 3 de-O-acylated monophosphoryl lipid A.

What is claimed is:  
     
       1. A vaccine composition comprising a hepatitis B antigen, 3-O-deacylated monophosphoryl lipid A and aluminum phosphate and further comprising a component selected from the group consisting of: a killed attenuated hepatitis A virus, diphtheria antigen, tetanus antigen, pertussis antigen, Haemophilus influenzae b (Hib) antigen, polio antigen, meningitidis A antigen, meningitidis B antigen, meningitidis C antigen and combinations thereof. 
     
     
       2. A vaccine composition according to  claim 1  further comprising a component selected from the group consisting of: aDTP (diptheria-tetanus-pertussis)-HBsAg combination, an Hib-HBsAg combination, a DTP-Hib-HBsAg combination and an IPV (inactivated polio vaccine)-DTP-Hib-HBsAg combination, and additionally comprising a killed attenuated hepatitis A virus. 
     
     
       3. A combination vaccine comprising a hepatitis B antigen, 3-O-deacylated monophosphoryl lipid A, aluminum phosphate and one or more components selected from the group consisting of: a killed attenuated hepatitis A virus, diphtheria antigen, tetanus antigen, pertussis antigen, Haemophilus influenzae b (Hib) antigen, polio antigen, meningitidis A antigen, meningitidis B antigen, and meningitidis C antigen. 
     
     
       4. A method of inducing neutralizing antibody titres in a human susceptible to or suffering from an infection by administering the vaccine combination as claimed in  claim 1 . 
     
     
       5. A method of preventing infections in humans which comprises administering an effective amount of the vaccine composition as claimed in  claim 1 . 
     
     
       6. A method of treating a human subject suffering from an ongoing infection comprising administrating an effective amount of a therapeutic vaccine composition as claimed in  claim 1 . 
     
     
       7. A method of inducing neutralizing antibody titres in a human susceptible to or suffering from an infection by administering the vaccine combination as claimed in  claim 3 . 
     
     
       8. A method of preventing infections in humans which comprises administering an effective amount of the vaccine composition as claimed in  claim 3 . 
     
     
       9. A method of treating a human subject suffering from an ongoing infection comprising administrating an effective amount of a therapeutic vaccine composition as claimed in  claim 3 . 
     
     
       10. A method of inducing neutralizing antibody titres in a human susceptible to or suffering from an infection by administering the vaccine combination as claimed in  claim 2 . 
     
     
       11. A method of preventing infections in humans which comprises administering an effective amount of the vaccine composition as claimed in  claim 2 . 
     
     
       12. A method of treating a human subject suffering from an ongoing infection comprising administrating an effective amount of a therapeutic vaccine composition as claimed in  claim 2 . 
     
     
       13. A vaccine composition according to  claim 1  wherein the killed attenuated hepatitis A virus is obtained from a HM- 175 strain of Hepatitis A virus. 
     
     
       14. A vaccine composition according to  claim 2  wherein the killed attenuated hepatitis A virus is obtained from a HM-175 strain of Hepatitis A virus. 
     
     
       15. A vaccine composition according to  claim 3  wherein the killed attenuated hepatitis A virus is obtained from a HM-175 strain of Hepatitis A virus.